← Back to Search

Smoking/Vaping Cessation Strategies for Nicotine Withdrawal (VASP Trial)

N/A

Recruiting

Led By Larry Hawk, PhD

Research Sponsored by State University of New York at Buffalo

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3.5 hours

Awards & highlights

VASP Trial Summary

This trial will compare the effects of smoking and vaping, helping to develop treatments for nicotine use, the leading preventable cause of death in the US.

Who is the study for?

This trial is for daily vapers or smokers with a nicotine level of 200+ ng/mL, who've been using these products for over 6 months. It's not open to those who use other tobacco products frequently, have high alcohol use scores, severe substance dependencies (excluding tobacco/nicotine), are on smoking cessation or antipsychotic meds, have major depression/suicide risk, or are pregnant.Check my eligibility

What is being tested?

The study aims to understand withdrawal in daily users of vaping devices compared to cigarette smokers by having them either abstain from nicotine for 24 hours or continue usage as desired. This research will help develop treatments for nicotine dependence.See study design

What are the potential side effects?

Since the interventions involve regular smoking/vaping habits and temporary abstinence rather than new medications, side effects may include typical withdrawal symptoms such as irritability, anxiety, difficulty concentrating, increased appetite and cravings.

VASP Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3.5 hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3.5 hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3.5 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Choice Behavior Under Cued Conditions (CBUCC) Task - crave cig

Choice Behavior Under Cued Conditions (CBUCC) Task - crave vape

Choice Behavior Under Cued Conditions (CBUCC) Task - spend cig

+45 more

Secondary outcome measures

Heart rate

Somatic/side effect checklist

modified Cigarette evaluation questionnaire

+1 more

Other outcome measures

Cotinine

Expired-air carbon monoxide

VASP Trial Design

3Treatment groups

Experimental Treatment

Group I: Daily Users of ENDSExperimental Treatment2 Interventions

Participants who use nicotine-containing ENDS daily or near-daily but who do NOT smoke combustible cigarettes daily or near-daily.

Group II: Daily Users of Combustible CigarettesExperimental Treatment2 Interventions

Participants who smoke combustible cigarettes daily or near-daily but do NOT use nicotine-containing ENDS daily or near-daily.

Group III: Daily Dual Users of ENDS and Combustible CigarettesExperimental Treatment2 Interventions

Participants who both use nicotine-containing ENDS and combustible cigarettes daily or near-daily

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Institute on Drug Abuse (NIDA)NIH

2,470 Previous Clinical Trials

2,619,361 Total Patients Enrolled

State University of New York at BuffaloLead Sponsor

247 Previous Clinical Trials

49,162 Total Patients Enrolled

Roswell Park Cancer InstituteOTHER

402 Previous Clinical Trials

30,737 Total Patients Enrolled

Media Library

Daily Users of ENDS Clinical Trial Eligibility Overview. Trial Name: NCT05772845 — N/A

Acute Abstinence From Cigarettes vs E-cigarettes (ENDS) Research Study Groups: Daily Users of ENDS, Daily Dual Users of ENDS and Combustible Cigarettes, Daily Users of Combustible Cigarettes

Acute Abstinence From Cigarettes vs E-cigarettes (ENDS) Clinical Trial 2023: Daily Users of ENDS Highlights & Side Effects. Trial Name: NCT05772845 — N/A

Daily Users of ENDS 2023 Treatment Timeline for Medical Study. Trial Name: NCT05772845 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the purpose of this medical study?

"The main purpose of this trial, lasting for approximately 3 hours, is to measure the Positive and Negative Affect Scale - PA 2.5. Other factors that will be evaluated include subjective/sensory aspects of vaping (modified e-Cigarette evaluation questionnaire), Heart rate (in beats per minute) and a Somatic/side effect checklist which assesses physical or psychological symptoms such as headache, fatigue or anxiety)."

Answered by AI

Is eligibility for this research restricted to individuals under a certain age?

"The age range of potential candidates that can be accepted in this trial is between 21 and 50 years old."

Answered by AI

How many participants are currently partaking in this clinical trial?

"Affirmative. Data hosted on clinicaltrials.gov demonstrates that this trial is actively recruiting, having first been published on February 14th 2023 and most recently updated in March 6th 2023. The study seeks to enrol 370 participants from one medical centre."

Answered by AI

Is my profile compatible with the prerequisites of this medical study?

"This clinical trial is seeking 370 participants aged between 21 and 50, who have entirely ceased all forms of smoking. Moreover, the use of e-cigarettes will also disqualify potential applicants from partaking in this research."

Answered by AI

Are there still slots available for individuals to partake in this trial?

"Affirmative. The information accessible on clinicaltrials.gov verifies that this scientific trial, which was initially posted on February 14th 2023, is actively recruiting volunteers. Approximately 370 individuals need to be recruited from one medical centre."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Vaping and Smoking Withdrawal Project

Larry Hawk, Ph.D. 2023. "Vaping and Smoking Withdrawal Project". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05772845.